Miflonil Breezhaler (Budesonide)

Budesonide binds to glucocorticoid receptors inside airway cells, altering gene expression to suppress the production of inflammatory cytokines and chemokines. This reduces the recruitment of inflammatory cells, stabilises lysosomal membranes, and ultimately diminishes airway swelling and hyper‑responsiveness, leading to better airflow.

The specific dose of Miflonil Breezhaler is determined by the prescribing clinician based on the patient’s age, disease severity, and response to therapy. Typical regimens may range from low to high inhalations per day, but the exact number of inhalations and strength should follow the prescriber’s written instructions.

Safety data for budesonide inhalation during pregnancy and lactation are limited, and the product’s pregnancy category is not definitively established. Clinicians should weigh potential benefits against possible risks, and the drug should only be used if clearly needed and prescribed by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Miflonil Breezhaler delivers budesonide via the Breezhaler device, offering consistent dose delivery and rapid onset. Compared with alternatives such as fluticasone propionate inhalers, budesonide generally has a similar anti‑inflammatory potency but may differ in particle size, device handling, and systemic exposure, which can influence patient preference and adherence.

Store Miflonil Breezhaler at room temperature, below 25 °C, in its original packaging. Keep the device away from moisture and direct sunlight. Do not expose the inhalation powder to extreme heat or humidity, and ensure the cap is securely closed when not in use to maintain dose integrity.

The patient loads a dose of budesonide powder into the Breezhaler device, inhales deeply through the mouthpiece, and holds the breath for several seconds to allow optimal lung deposition. Proper technique—including a slow, steady inhalation and regular device cleaning—should be demonstrated and reviewed by a healthcare professional.

Serious adverse events, although uncommon, include adrenal suppression, which can affect the body’s stress response; pneumonia, especially in patients with COPD; and paradoxical bronchospasm, a sudden worsening of breathing shortly after inhalation. Patients should be instructed to seek immediate medical attention if they experience severe shortness of breath or unusual symptoms.

Miflonil Breezhaler is contraindicated in individuals with a known hypersensitivity to budesonide or any component of the formulation. It should also be avoided during acute episodes of severe bronchospasm until the condition is stabilized, and used with caution in patients with active, untreated infections or uncontrolled systemic diseases.